On the other hand, depletion of DE Tfh cells via <i>Ezh2</i> gene deletion, inhibition of EZH2 (using FDA-approved drug, tazemetostat), or anti-CXCR6 mAb led to tumor regression. Here, CXCR6 is linked to neoplasm.